Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study
2018
Anemia is an inevitable complication of hemodialysis, and the primary cause is erythropoietin deficiency. After diagnosis, treatment begins with an erythropoiesis-stimulating agent (ESA). However, some patients remain anemic even after receiving this medication. This study aimed to investigate the factors associated with resistance to recombinant human erythropoietin therapy with epoetin alfa (αEPO). We performed a prospective, longitudinal study of hemodialysis patients receiving treatment with αEPO at our reference hospital from July 2015 to June 2016. Clinical data was collected, and [...]
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
39
References
10
Citations
NaN
KQI